BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, June 20, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

June 20, 2019

View Archived Issues

Recruitment ongoing in Immunocore's first-in-human study of IMC-C103C

Read More

Boston Pharmaceuticals begins phase IIa study of BOS-589 in IBS-D

Read More

Norovirus' bright side

Read More

Beactica receives grant to advance research on preclinical candidate BEA-17 for glioblastoma

Read More

BeiGene, SpringWorks form MapKure to develop next-generation RAF kinase inhibitor BGB-3245

Read More

Phase I/II study of nivolumab plus radical surgery in microsatellite stable LARC

Read More

Muscle CB1R regulates whole-body metabolism and physical performance, novel mouse model shows

Read More

Cellular lung map gives asthma, other insights

Read More

Recruitment ongoing in phase I study of VSV-IFNb-TYRP1 for the treatment of melanoma

Read More

Arch Biopartners initiates phase I study of Metablok

Read More

Positive early safety and efficacy results of phase I/II study of nomacopan in AKC

Read More

Updated positive results for phase Ib study of resiniferatoxin in knee osteoarthritis pain

Read More

Apatinib monotherapy shows promising efficacy and manageable toxicities in mCRC

Read More

Durvalumab in combination with R-CHOP shows promising response rates in high-risk DLBCL

Read More

Abatacept misses primary endpoint in Sjogren's syndrome in phase III study

Read More

Step Pharma discovers new CTP synthase 1 inhibitors

Read More

5-HT7 antagonists patented by KAIST, KIST

Read More

Servier, Vernalis disclose ubiquitin carboxyl-terminal hydrolase 7 inhibitors

Read More

Disulfiram and copper with concurrent RT and temozolomide for glioblastoma: phase I/II trial

Read More

Janssen presents compound for respiratory syncytial virus infections

Read More

New Janus kinase inhibitors synthesized at Korea Pharma

Read More

Loss of NFASC NF186 isoform tied to hereditary ataxia

Read More

New phase I study evaluates TBX-3400 in stage III/IV melanoma resistant or refractory to immune CPIs

Read More

GSK initiates phase III trials of GSK-3196165 in moderate to severely active rheumatoid arthritis

Read More

DiaMedica reports phase Ib interim data on DM-199 in chronic kidney disease

Read More

PCYT2 gene mutations seen to cause neurological disorder

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 18, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 16, 2026
  • Brain with puzzle piece removed

    Gene replacement rescues autism-related phenotypes in mice

    BioWorld Science
    Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
  • Red blood cells, DNA

    For clonal hematopoiesis, epigenetics can be in driver’s seat

    BioWorld Science
    Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
  • Illustration of amyloid plaques in Alzheimer's disease

    Elixiron’s enrupatinib shows upbeat interim phase II AD results

    BioWorld
    Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing